Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 13;14(8):e0220108.
doi: 10.1371/journal.pone.0220108. eCollection 2019.

Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study - 2012 - 2015

Dorthe Raben  1 , Ann Kathleen Sullivan  2 , Amanda Mocroft  3 , Galyna Kutsyna  4 , Vesna Hadžiosmanović  5 , Anna Vassilenko  6 , Nikoloz Chkhartisvili  7 , Viktar Mitsura  8 , Court Pedersen  9 , Jane Anderson  10 , Josip Begovac  11 , Ulrik Bak Dragsted  12 , Barbara Bertisch  13 , Anna Grzeszczuk  14 , Jane Minton  15 , Valentina Coca Necsoi  16 , Maria Kitchen  17 , Faiza Ajana  18 , Anton Sokhan  19 , Laura Comi  20 , Paymaneh Farazmand  21 , Dragica Pesut  22 , Stephane De Wit  16 , José Maria Gatell  23 , Brian Gazzard  2 , Antonella d'Arminio Monforte  24 , Jürgen Kurt Rockstroh  25 , Yazdan Yazdanpanah  26   27 , Karen Champenois  27 , Marie Louise Jakobsen  1 , Jens Dilling Lundgren  1 ; HIDES Study Group
Affiliations

Improving the evidence for indicator condition guided HIV testing in Europe: Results from the HIDES II Study - 2012 - 2015

Dorthe Raben et al. PLoS One. .

Abstract

Background: It is cost-effective to perform an HIV test in people with specific indicator conditions (IC) with an undiagnosed HIV prevalence of at least 0.1%. Our aim was to determine the HIV prevalence for 14 different conditions across 20 European countries.

Methods: Individuals aged 18-65 years presenting for care with one of 14 ICs between January 2012 and June 2014 were included and routinely offered an HIV test. Logistic regression assessed factors associated with testing HIV positive. Patients presenting with infectious mononucleosis-like syndrome (IMS) were recruited up until September 2015.

Results: Of 10,877 patients presenting with an IC and included in the analysis, 303 tested positive (2.8%; 95% CI 2.5-3.1%). People presenting with an IC in Southern and Eastern Europe were more likely to test HIV positive as were people presenting with IMS, lymphadenopathy and leukocytopenia/ thrombocytopenia. One third of people diagnosed with HIV after presenting with IMS reported a negative HIV test in the preceding 12 months. Of patients newly diagnosed with HIV where data was available, 92.6% were promptly linked to care; of these 10.4% were reported lost to follow up or dead 12 months after diagnosis.

Conclusion: The study showed that 10 conditions had HIV prevalences > 0.1%. These 10 ICs should be adopted into HIV testing and IC specialty guidelines. As IMS presentation can mimic acute HIV sero-conversion and has the highest positivity rate, this IC in particular affords opportunities for earlier diagnosis and public health benefit.

PubMed Disclaimer

Conflict of interest statement

The HIDES study was funded by the HIV in Europe initiative which has received unrestricted funding from Gilead Sciences, ViiV Healthcare, Merck, Tibotec, Pfizer, Schering-Plough, Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline. This does not alter our adherence to PLOS ONE policies on sharing data and materials. AM has received honoraria and consultancy fee from Gilead Sciences and ViiV Healthcare. JG has received honoraria and grants from ViiV Healthcare, MSD, Gilead Sciences and Janssen and is by 1 May 2018 employed by ViiV Healthcare. JR has received honoraria and consultancy fee from ViiV Healthcare, Merck/MSD, Gilead Sciences, Abbott, Abbvie, Abivax, Janssen. YY has received speaker and consultancy fee from Abbott, BMS, Gilead Sciences, MSD, Roche, Tibotec and ViiV Healthcare. KC has received consultancy and speaker fee from Gilead. All other authors declare no conflict of interest.

Figures

Fig 1
Fig 1. Prevalence of testing HIV positive: HIDES II study.
Fig 2
Fig 2. Adjusted odds of testing HIV positive.
See this image and copyright information in PMC

References

    1. Sullivan AK, Raben D, Reekie J, Rayment M, Mocroft A, Esser S et al. Feasibility and Effectiveness of Indicator Condition Guided Testing for HIV: Results from HIDES I (HIV Indicator Diseases across Europe Study) PLoS One. 2013; 8(1): e52845 10.1371/journal.pone.0052845 - DOI - PMC - PubMed
    1. Yazdanpanah Y, Sloan CE, Charlois-Ou C, Le Vu S, Semaille C, Costagliola D et al. Routine HIV screening in France: clinical impact and cost effectiveness. PLoS One. 2010. October 1;5 (10): e13132 10.1371/journal.pone.0013132 - DOI - PMC - PubMed
    1. Bert F, Gualano MR, Biancone P, Brescia V, Camussi E, Martorana M, et al. Cost-effectiveness of HIV screening in high-income countries: A systematic review. Article in Press: Corrected Proof. Health Policy. 2018. May; 122(5):533–547. Epub 2018 Mar 23 10.1016/j.healthpol.2018.03.007 - DOI - PubMed
    1. HIV Indicator Conditions: Guidance for Implementing HIV Testing in Adults in Health Care Settings. Copenhagen, Copenhagen University, 2012. Available from: http://hiveurope.eu/Portals/0/Documents/Guidance.pdf.pdf?ver=2014-01-29-...
    1. Gazzard B, Clumeck N, Monforte AD, Lundgren DL. Indicator disease‐guided testing for HIV–the next step for Europe? HIV Medicine. 2008. July;9(s2):34–40. - PubMed

Publication types